pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
KRAS · news · pharmadog
← back to KRAS
News · KRAS
170
stories
1d
STAT+: FDA rejects Capricor Therapeutics’ Duchenne therapy, a decision that was a long time coming
stat
1d
ICE detention of Princeton scientist rattles academia
stat
1d
Erasca data add to pressure facing Revolution’s breakthrough cancer drug
biopharma dive
1d
KRAS at Triple Meeting: Erasca wants to one-up RevMed, while Alterome tries a different approach
endpoints
1d
RevMed pads Rasonque’s first-line survival advantage in pancreatic cancer with early data
biospace
1d
STAT+: Early results for Alterome’s KRAS drug for pancreas, lung and colon cancer arrive
stat
2d
STAT+: Lawmakers want U.S. biotech to outcompete China
stat
2d
STAT+: Peptide market poised to explode with new Hims and Noom launches
stat
2d
STAT+: Merck, Isomorphic Labs partner to develop oncology drug candidates
stat
2d
STAT+: In cancer drug development, the spotlight shifts onto Erasca’s KRAS-targeted treatment
stat
12d
FDA orders class-wide GLP-1 label update to include potential risk for rare eye disease
biospace
12d
MedWatch Alert: FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition: FDA Safety Communication
fda medwatch
16d
Rasonque sales drive RevMed's stock; whistleblower sues Madrigal over MASH
endpoints
16d
RevMed’s Rasonque shatters analyst estimates with $198M quarter
biospace
16d
STAT+: Revolution Medicines’ pancreatic cancer drug has stunning commercial debut
stat
18d
Pfizer pares back obesity pipeline, drops phase 2-stage lung disease candidate
fiercebiotech
19d
Drugmakers rush to pair up with Summit’s ivonescimab ahead of key verdict
biospace
22d
Once undruggable, the Wnt/B-catenin pathway shows increasing promise
biospace
23d
Chutes & Ladders—Lilly unifies global markets as 36-year vet Patrik Jonsson retires
fiercebiotech
24d
5 new drug launches that defied industry expectations
biospace
25d
STAT+: RFK Jr. goes for broke in Iowa
stat
25d
STAT+: Nonprofit resurrects shelved gene therapy after startup shuts down
stat
25d
EMSO 2026: Incyte a ‘firm contender’ in G12D pancreatic cancer race as early candidate shines
biospace
25d
A possible treatment for brain-eating amoebas, found in the sea
stat
25d
STAT+: Pennsylvania Dutch country, tired of waiting for biopharma, builds drug company of its own
stat
25d
Opinion: Cancer vaccines are finally here. How do we get them to patients?
stat
25d
From RAS rivalries to leaked cancer vaccine readouts, ESMO brought the data drama
fiercebiotech
26d
STAT+: Roche gets a lung cancer win with its KRAS drug divarasib
stat
26d
ESMO ‘26: A cancer vaccine debate, Roche’s KRAS progress and Amgen’s ‘unprecedented’ data
biopharma dive
26d
STAT+: Incyte pancreatic cancer medicine induces lasting tumor responses, company says at ESMO
stat
← prev
page 1 of 6
next →